bioAffinity Technologies, Inc. BIAF 深 沪
等待开盘 05-12 09:30:00 美东时间
1.98
-0.060
-2.94%
华盛通- 最 高2.21
- 今 开1.93
- 成交量 15.79万股
- 最 低 1.81
- 昨 收 2.04
- 总市值 540.06万
- 52周最高 7.29
- 市盈率 静 --
- 换手率 5.79%
- 52周最低 0.134
- 委 比 -99.13%
- 总股本 272.76万
- 历史最高 15.55
- 量 比 0.90
- 振 幅 19.61%
- 历史最低 0.134
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多bioAffinity Technologies Reports Q1 CyPath Lung Diagnostic Unit Sales Up 146% YoY
Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivorsFlow cytometry+AI
04-01 20:08
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings
US stocks started higher this morning, with NASDAQ up over 100 points. Energy shares rose by 1.3%, while Aldeyra and Meiwu Tech saw sharp declines.
03-17 22:19
Crude Oil Gains Over 1%; VEON Shares Spike Higher
US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services down 1.2%. PCE index rose 2.8%, GDP up 0.7%.
03-14 01:01
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies shares are trading higher Friday after it reported FY25 results with strong growth in CyPath Lung diagnostic.
03-13 22:30
bioAffinity Technologies' CyPath Lung Test Shows Potential Significant Healthcare Savings By Reducing Unnecessary Follow-Up, Medical Complications And Overdiagnosis In Peer-Reviewed Study
Study by BAMC's Michael Morris, M.D., and VA's Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of lung cancerA new economic study found that adding CyPath® Lung,
2024-09-18 20:10
